These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 30911053)
21. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. Savva A; Raftogiannis M; Baziaka F; Routsi C; Antonopoulou A; Koutoukas P; Tsaganos T; Kotanidou A; Apostolidou E; Giamarellos-Bourboulis EJ; Dimopoulos G J Infect; 2011 Nov; 63(5):344-50. PubMed ID: 21839112 [TBL] [Abstract][Full Text] [Related]
22. Soluble ICAM-1 is modulated by hyperbaric oxygen treatment and correlates with disease severity and mortality in patients with necrotizing soft-tissue infection. Hedetoft M; Moser C; Jensen PØ; Vinkel J; Hyldegaard O J Appl Physiol (1985); 2021 Mar; 130(3):729-736. PubMed ID: 33444122 [TBL] [Abstract][Full Text] [Related]
23. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit. El-Mekkawy MS; Saleh NY; Sonbol AA Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717 [TBL] [Abstract][Full Text] [Related]
24. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis. Vassiliou AG; Zacharis A; Vrettou CS; Keskinidou C; Jahaj E; Mastora Z; Orfanos SE; Dimopoulou I; Kotanidou A Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626416 [TBL] [Abstract][Full Text] [Related]
26. Hyperbaric oxygen treatment is associated with a decrease in cytokine levels in patients with necrotizing soft-tissue infection. Hedetoft M; Garred P; Madsen MB; Hyldegaard O Physiol Rep; 2021 Mar; 9(6):e14757. PubMed ID: 33719215 [TBL] [Abstract][Full Text] [Related]
27. Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis. Zhang Q; Li L; Chen H; Zhang G; Zhu S; Kong R; Chen H; Wang G; Sun B J Clin Lab Anal; 2020 Mar; 34(3):e23097. PubMed ID: 31774228 [TBL] [Abstract][Full Text] [Related]
28. Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study. Luo Q; Ning P; Zheng Y; Shang Y; Zhou B; Gao Z Crit Care; 2018 Jan; 22(1):15. PubMed ID: 29368632 [TBL] [Abstract][Full Text] [Related]
29. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study. Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J; Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800 [TBL] [Abstract][Full Text] [Related]
30. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. Uusitalo-Seppälä R; Huttunen R; Tarkka M; Aittoniemi J; Koskinen P; Leino A; Vahlberg T; Rintala EM J Intern Med; 2012 Sep; 272(3):247-56. PubMed ID: 22755554 [TBL] [Abstract][Full Text] [Related]
31. Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection. Hedetoft M; Hansen MB; Madsen MB; Johansen JS; Hyldegaard O BMC Infect Dis; 2021 Oct; 21(1):1046. PubMed ID: 34627195 [TBL] [Abstract][Full Text] [Related]
32. Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality. Chen D; Wu X; Yang J; Yu L Exp Ther Med; 2019 Oct; 18(4):2984-2992. PubMed ID: 31555383 [TBL] [Abstract][Full Text] [Related]
33. Prognostic evaluation of severe sepsis and septic shock: procalcitonin clearance vs Δ Sequential Organ Failure Assessment. de Azevedo JR; Torres OJ; Beraldi RA; Ribas CA; Malafaia O J Crit Care; 2015 Feb; 30(1):219.e9-12. PubMed ID: 25241933 [TBL] [Abstract][Full Text] [Related]
34. Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity. Lipinski M; Rydzewska-Rosolowska A; Rydzewski A; Cicha M; Rydzewska G Pancreatology; 2017; 17(1):24-29. PubMed ID: 27914940 [TBL] [Abstract][Full Text] [Related]
35. Value of the soluble urokinase-type plasminogen activator receptor as a predictor of prognosis in patients attended in hospital emergency departments. Herrero-Puente P; Eugen-Olsen J; Ferreras Amez JM; Gamazo Del Río J; Prieto-García B; de Las Heras-Vallelado A; Arribas Entrala B; González Del Castillo J Emergencias; 2024 Jan; 36(1):17-24. PubMed ID: 38318738 [TBL] [Abstract][Full Text] [Related]
36. Soluble urokinase plasminogen activator receptor: a novel biomarker of pediatric community-acquired and hospitalacquired pneumonia. El-Mekkawy MS; Soliman SE; Saleh NY Turk J Pediatr; 2022; 64(1):98-109. PubMed ID: 35286036 [TBL] [Abstract][Full Text] [Related]
37. Long-term quality of life in necrotizing soft-tissue infection survivors: a monocentric prospective cohort study. Urbina T; Canoui-Poitrine F; Hua C; Layese R; Alves A; Ouedraogo R; Bosc R; Sbidian E; Chosidow O; Dessap AM; de Prost N; Ann Intensive Care; 2021 Jul; 11(1):102. PubMed ID: 34213694 [TBL] [Abstract][Full Text] [Related]
38. Role of soluble urokinase plasminogen activator receptor in critically ill children with hospital-acquired pneumonia: an observational study in hospital with controls. Saleh NY; Soliman SE; Aboukoura MA; Garib MI BMJ Paediatr Open; 2024 Jan; 8(1):. PubMed ID: 38176706 [TBL] [Abstract][Full Text] [Related]